Registered & Corporate Office:
AMANTA HEALTHCARE LIMITED
8th Floor, Shaligram Corporates, CJ Marg,
Ambli, Ahmedabad–380058, Gujarat, INDIA.
Tel.: 079 – 67777600
Email: info@amanta.co.in
Website: www.amanta.co.in

CIN: L24139GJ1994PLC023944

Date: August 5, 2026

To, Sr. General Manager Listing Department **BSE Limited** Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. Scrip Code: **544502**	To, Sr. General Manager **National Stock Exchange of India Limited** Exchange Plaza, C-1, Block G Bandra Kurla Complex Bandra (E), Mumbai – 400 051. Trading Symbol: **AMANTA**

Dear Sir / Madam,

Sub: Outcome under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") for the meeting of Board of Directors of the Company held today on August 05, 2026.

With reference to the captioned subject, we would like to inform that the Board of Directors of Amanta Healthcare Limited at its meeting held today, i.e. on Wednesday, August 5, 2026 have inter-alia considered and approved:

1. The Financial Results of the Company for the quarter ended June 30, 2026.

2. Limited Review Report of the Auditors with unmodified opinion of the Company for the quarter ended June 30, 2026.

3. Considered and approved the Board's Report of the company for the Financial Year ended on 31st March, 2026.

4. Approved the Notice convening the 31st Annual General Meeting (AGM) of the Company proposed to be held on Wednesday, September 16, 2026, at 12:00 P.M. IST through Video Conferencing (VC)/Other Audio Visual Means (OAVM), deemed to be held at the Registered Office of the Company.

5. Approved the appointment of Mr. Kashyap R. Mehta (Membership No. 1821), Partner of M/s. Kashyap R. Mehta and Partners, Practicing Company Secretaries, Ahmedabad, as the Scrutinizer for conducting the remote e-voting process and e-voting during the AGM in a fair and transparent manner.

6. Approved the dissolution of IPO Committee w.e.f. August 05, 2026. The IPO Committee was initially constituted on August 24, 2024 to oversee and make decisions related to the initial public offering, in compliance with the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018.

The detailed disclosures as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is enclosed herewith.

The Meeting Commenced at 04:30 P.M. and concluded at 05:35 P.M.

You are requested to take the same on your records.

Thanking you,

Yours faithfully,

FOR, AMANTA HEALTHCARE LIMITED

Dinodia Nikhita

Digitally signed by Dinodia Nikhita
DN: c=IN, o=Personal, title=8566, pseudonym=2110201e1d024716bc7c8cb71aee2c6c, 2.5.4.20=de51f0a5a2bf09c322653af79eb52283df1d5f06355edec1ca4d84b91a1a643a, postalCode=380028, st=Gujarat, serialNumber=81b8bd656eb87ef922a9a651aad1a8cbaf1069644ddf48b498a62779ad541684, cn=Dinodia Nikhita
Date: 2026.08.05 18:31:06 +05'30'

NIKHITA DINODIA
COMPANY SECRETARY & COMPLIANCE OFFICER

Price Waterhouse Chartered Accountants LLP

Review Report

To
The Board of Directors
Amanta Healthcare Limited
8th Floor, Shaligram Corporates, C.J. Marg,
Ambli, Ahmedabad 380058
Gujarat, India

1. We have reviewed the unaudited financial results of Amanta Healthcare Limited (the "Company") for the quarter ended June 30, 2026, which are included in the accompanying 'Statement of Unaudited Financial Results for the quarter ended June 30, 2026' (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been digitally signed by us for identification purposes.

2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse Chartered Accountants LLP
Firm Registration Number: 012754N/N500016

DEVANG
ASHOKBHAI MEHTA

Digitally signed by DEVANG
ASHOKBHAI MEHTA
Date: 2026.08.05 17:49:09
+05'30'

Devang Mehta
Partner
Membership Number: 118785
UDIN: 26118785DTQTJT5703

Place: Mumbai
Date: August 05, 2026

AMANTA HEALTHCARE LIMITED					
Registered Office: 8th Floor, Shaligram Corporates C.J. Marg, Ambli, Ahmedabad - 380058, Gujarat, India, CIN: L24139GJ1994PLC023944. Phone: +91 79 6777 7600, E-mail: info@amanta.co.in, Website: www.amanta.co.in					
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026					
					(Rs. in lakhs)
Sr.no.	**Particulars**	**For the quarter ended**			**For the year ended**
		30.06.2026 Un-audited	**31.03.2026 Un-audited**	**30.06.2025 Un-audited**	**31.03.2026 Audited**
I	**Income**				
	Revenue from operations	6,880.32	7,699.49	6,530.71	28,767.67
	Other income	64.30	166.21	96.09	337.07
	Total income	**6,944.62**	**7,865.70**	**6,626.80**	**29,104.74**
II	**Expenses**				
	Cost of material consumed	2,272.90	2,513.04	2,383.11	9,692.95
	Purchase of stock-in-trade	284.21	354.58	308.49	1,060.90
	Changes in inventories of finished goods, work-in-process and stock-in-trade	(493.24)	19.08	(879.20)	(1,089.29)
	Employee benefits expense	1,158.44	1,108.84	1,014.72	4,296.11
	Finance costs	600.48	424.64	628.69	2,074.57
	Depreciation and amortisation expense	468.53	475.18	464.09	1,873.00
	Other expenses	2,204.07	2,208.67	2,214.25	8,821.15
	Total expenses	**6,495.39**	**7,104.03**	**6,134.15**	**26,729.39**
III	**Profit before exceptional item and tax for the period / year (I-II)**	**449.23**	**761.67**	**492.65**	**2,375.35**
IV	**Exceptional item (Refer note 5)**	**-**	**-**	**-**	**262.88**
V	**Profit before tax (III - IV)**	**449.23**	**761.67**	**492.65**	**2,112.47**
VI	**Tax expense**				
	- Current Tax	34.76	292.98	165.19	855.53
	- Tax adjustment in respect of earlier year	-	-	-	3.43
	- Deferred Tax	83.42	(84.47)	(23.26)	(234.01)
	Total tax expenses	**118.18**	**208.51**	**141.93**	**624.95**
VII	**Profit for the period/year (V-VI)**	**331.05**	**553.16**	**350.72**	**1,487.52**
VIII	**Other comprehensive income**				
	Items that will not be reclassified to profit and loss				
	Remeasurement (loss) on the defined benefit plans	(24.14)	(56.33)	(13.41)	(96.55)
	Tax relating to remeasurement (loss) of the defined benefit plans	6.07	14.18	3.37	24.30
	Other comprehensive income (net of tax)	**(18.07)**	**(42.15)**	**(10.04)**	**(72.25)**
IX	**Total comprehensive income (VII+VIII)**	**312.98**	**511.01**	**340.68**	**1,415.27**
	Paid up equity share capital (Face value of Rs. 10/- each)	388.29	343.36	288.29	343.36
	Reserves excluding revaluation reserves as per balance sheet of previous accounting year				18,138.16
	Earnings / (Loss) per share (of Rs. 10/- each) (not annualised)				
	Basic and Diluted (Rs.)	0.85	1.61	1.22	4.33
	* not annualised	*	*	*	

Notes:

1 The above unaudited financial results have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act 2013, read with Companies (Indian Accounting Standards) Rules, 2015, as amended and other accounting principles generally accepted in India. The above unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 05, 2026.

2 Figures of the quarter ended March 31, 2026 are the balancing figures between the audited figures for the year ended March 31, 2026 and the unaudited published year to date figures up to the nine months period ended December 31, 2025.

3 The Company operates only in one business segment i.e. Manufacturing and sale of pharmaceutical products including contract manufacturing services provided to customer which constitutes single reportable segment in accordance with the requirements of Ind AS 108 "Operating Segments".

4 During the previous year, the Company completed its Initial Public Offer (IPO) where 10,000,000 equity shares of face value of Rs. 10 each were issued at a price of Rs. 126 per share. The issue comprised of 100% fresh issue aggregating to Rs. 12,600 lakhs. Pursuant to IPO, the equity shares of the Company were listed on BSE Limited and National Stock Exchange of India Limited on September 09, 2025. The utilization of the IPO proceeds from fresh issue of Rs. 12,600 lakhs is summarized below: -

Particulars	**Amount to be utilized as per prospectus (Rs. In lakhs)**	**Revised Cost of objects (Rs. in lakhs) ***	**Amount utilized upto June 30, 2026 (Rs. In lakhs)**	**Amount unutilized as at June 30, 2026 (Rs. In lakhs) [Refer Note (a) below]**	**Delay in utilisation**
Funding capital expenditure requirements for civil construction work and towards purchase of equipment, plant and machinery for setting up new manufacturing line of SteriPort at Hariyala, Kheda, Gujarat	7,000.00	7,000.00	6,004.87	995.13	(i) Budgeted for FY 2025-26: Rs. 7,000 lakhs (ii) Unutilised: Rs. 995.13 lakhs, refer note (b) below
Funding capital expenditure requirements towards civil construction work, purchase of equipment, plant and machinery for setting up new manufacturing line for SVP at Hariyala, Kheda, Gujarat	3,013.11	3,013.11	745.88	2,267.23	(i) Budgeted for FY 2025-26: Rs. 1,000 lakhs (ii) Unutilised: Rs. 254.12 lakhs, refer note (b) below
General corporate purposes*	660.46	302.08	302.08	-	
Issue Expenses*	1,926.43	2,284.81	2,284.81	-	
Total	**12,600.00**	**12,600.00**	**9,337.64**	**3,262.36**	

* During the quarter ended September 30, 2025, the issue expenses were modified to the extent of GST payment made over the cost as per the Offer Document filed for the IPO as certified by Independent Chartered Accountant and affirmed by the monitoring agency. Consequent to this, general corporate purpose expenses was also modified and reduced to that extent.

Note (a): IPO proceeds which were unutilised as at June 30, 2026 are temporarily invested in fixed deposits and kept in monitoring account. Interest earned on fixed deposits and unutilised for the objects is Rs. 83.10 lakhs and interest accrued on the fixed deposits as at June 30, 2026 is Rs. 27.81 lakhs.

Note (b): The Company had estimated to utilize Rs 8,000 lakhs for the above mentioned objects by FY 2026. The delay is primarily attributable to (a) deferment of payments to suppliers on account of pending completion of work/supply of goods against agreed milestones; and (b) delay in placement of machinery orders owing to pending finalization of commercial terms with the respective suppliers.

5 The Company incurred certain IPO related expenses in the year ended March 31, 2026, which were allocated on a rational basis. The cost of Rs. 1,719.16 lakhs (net of GST) allocated for issue of new shares was adjusted against securities premium as permissible under Section 52 of the Companies Act, 2013 upon successful completion of Initial Public Offer (IPO). The cost of Rs. 262.88 lakhs (net of GST) allocated for listing of existing shares was recognised in the Statement of Profit and Loss and was disclosed as an exceptional item.

The Statutory Auditors have digitally signed these Unaudited Financial Results for identification purposes only, and these Unaudited Financial Results should be read in conjunction with their Limited Review Report dated August 05, 2026.

DEVANG ASHOKBHAI MEHTA

Digitally signed by DEVANG ASHOKBHAI MEHTA
Date: 2026.08.05 17:48:34 +05'30'

For and on behalf of Board of Directors

Bhavesh Girishbhai Patel

Digitally signed by Bhavesh Girishbhai Patel

Bhavesh Patel
Chairman and Managing Director
DIN: 00085505

Place: Ahmedabad
Date: August 05, 2026